Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

A new 'idol' grabs the spotlight

15.06.2009
UCLA study discovers enzyme that controls 'bad' cholesterol

BACKGROUND: Low-density lipoprotein (LDL) is the so-called "bad cholesterol" often linked to medical problems like heart disease and clogged arteries. Cells in the liver produce a specific receptor that sticks to LDL and removes it from the blood, lowering cholesterol levels. Statin drugs also reduce LDL cholesterol levels by boosting cells' production of the receptor.

FINDINGS: Using a mouse model, UCLA scientists discovered a new mechanism that controls cells' production of LDL receptor. The team identified an enzyme called Idol that destroys the receptor, permitting more LDL cholesterol to circulate in the blood. In blocking Idol's activity, the researchers triggered cells to make more receptor and absorb more cholesterol from the body.

"We only know of three pathways that regulate the LDL receptor. The first two are already targeted by existing drugs," explained Dr. Peter Tontonoz, professor of pathology and laboratory medicine at the David Geffen School of Medicine at UCLA and an investigator at the Howard Hughes Medical Institute. "Idol is the first mechanism discovered in several years that may lead to a new medication designed to control cholesterol levels."

IMPACT: The findings suggest that development of a drug that interferes with Idol's activity could influence cholesterol metabolism and lower levels of bad cholesterol. Doctors could prescribe the new medication in conjunction with statin drugs, which also cut cholesterol levels by targeting a different enzyme linked to the LDL receptor. This could benefit patients that cannot tolerate statin-related side effects.

AUTHORS: Tontonoz collaborated with Noam Zelcer, Cynthia Hong and Rima Boyadjian. The research was funded by the Howard Hughes Medical Institute and the National Heart, Lung and Blood Institute. Tontonoz and Zelcer have filed a patent related to the research findings.

JOURNAL: The research appears in the June 11 online edition of the journal Science.

GRAPHICS: Image showing how the LDL receptor changes appearance after contact with the Idol enzyme.

Elaine Schmidt | EurekAlert!
Further information:
http://www.ucla.edu

More articles from Life Sciences:

nachricht Researchers uncover protein-based “cancer signature”
05.12.2016 | Universität Basel

nachricht The Nagoya Protocol Creates Disadvantages for Many Countries when Applied to Microorganisms
05.12.2016 | Leibniz-Institut DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

IHP presents the fastest silicon-based transistor in the world

05.12.2016 | Power and Electrical Engineering

InLight study: insights into chemical processes using light

05.12.2016 | Materials Sciences

High-precision magnetic field sensing

05.12.2016 | Power and Electrical Engineering

VideoLinks
B2B-VideoLinks
More VideoLinks >>>